|
Shire Presents Positive DataZacks.comRecently, Shire Plc. (SHPGY - Snapshot Report) presented data from a late stage trial of Vyvanse, which was conducted to study the safety and efficacy of ...and more » |
The drug is for the treatment of attention-deficit hyperactivity disorder in children and adolescents aged 6 to 17 years.
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with 17 Years, Adolescents, Attention Deficit Hyperactivity, Attention Deficit Hyperactivity Disorder, Deficit Hyperactivity Disorder, Fda, Fda Approval, Hyperactivity, Yahoo, Yahoo Finance, Zacks
